We have 15+ years of experience with Methoxy Polyethylene Glycol (mPEG) and activated mPEG development and manufacturing. We perform mPEG development at our R and D center in Hyderabad. Our team has extensive experience in synthesis, analysis, purification and troubleshooting of mPEG derivatives and have technical capabilities in synthetic route design to incorporate various activating groups and help customize products as per end applications.
Aurigene is a leading manufacturer and supplier of Methoxy Polyethylene Glycol (mPEGs) and activated Methoxy Polyethylene Glycol (mPEGs) which are used for the conjugation of proteins, antibody fragments and peptides. With our GMP manufacturing capabilities and backward integration to highly pure Methoxy PEG-OH, we guarantee the quality and security of the supplies of our activated Methoxy PEGs (mPEGs) products.
As a leading CDMO, we understand customer requirements and customize our products to meet the client’s requirements. Currently, we serve multiple customers in various products such as diagnostic players, other mPEG suppliers, and big pharma using mPEG for advanced therapeutics. In addition, our backward integration of key raw materials makes it possible to ensure a sustainable quality of the final activated mPEG throughout the manufacturing process.
We have technical capabilities in synthetic route design to incorporate the activating group and help customize products as per end applications. Our centers at Hyderabad and Mirfield are equipped with advanced instruments to enable the scale-up of activated mPEG production up to 90 kg per batch.
Successful custom PEGylation requires several factors to be optimized such as the site of PEGylation, chain length, and mPEG linkers. Determining the optimum mPEG may require the testing of several activated mPEGs at different chain lengths. We offer a range of activated linear mPEGs to enable our customers to find the ideal mPEG for conjugation of the required quality, with high levels of activation, narrow polydispersity and low diol content.
mPEG-OH is the key raw material for the synthesis of activated PEGs. Our backward integration of key raw materials makes it possible to ensure a sustainable quality of the final activated mPEG throughout the manufacturing process. Our process to make high quality pharmaceutical grade mPEG-OH is patent protected. We manufacture mPEG alcohols in our Cuernavaca, Mexico site.
We support the production of mPEG-OH of molecular weight ranging from 2kDa, 5kDa, 10kDa, 20kDa, 30kDa, 40kDa, and 50kDa.
We are specialists in liner-activated mPEG. Our range of products includes various activating groups such as
We support the production of mPEG derivatives of molecular weight ranging from 2kDa, 5kDa, 10kDa, 20kDa, 30kDa, 40kDa, and 50kDa.
We help aid our customers with supplies for their development and clinical purposes. We manufacture mPEG derivatives from our Mirfield, UK and Hyderabad, India sites. Key features of our sites are as below:
The analysis of large polymeric materials such as PEGs can be challenging. Our analytical lab is equipped with advanced equipment and analytical instruments to determine the quality of our highly pure mPEGs.
Also, we have a highly experienced analytical team who can characterize the compounds for any required impurity specifications and develop as well as validate such methods.
We perform all critical analytical tests in-house such as:
Technical know-how to deliver the most challenging specifications
Experience and legacy of working with big pharma clients
US FDA audited facilities
Backward integration of mPEG alcohol
FEBRUARY 08, 2021
PROteolysis TArgeting Chimeras (PROTAC) are a series of hetero-bifunctional molecules that hijack the body’s natural disposal system to initiate selective degradation of the protein of interest (POI). They are generally bifunctional molecules that hijack the Ubiquitin Proteasome System (UPS) to achieve the total degradation of a disease-related target protein. ...Read More
Peptides are short chains of amino acids that are linked by peptide bonds. Several peptides linked together are called polypeptides. A protein contains one or more polypeptides. Therefore, proteins are long chains of amino acids held together by peptide bonds....Read More
Aurigene Pharmaceutical Services off end-to-end formulation development and manufacturing services fm pr-formulations, clinical development, clinical supplies to commercial manufacturing. ...Read More
Challenges: The evaluation of Evans Blue Dye (EBD) by fluorescence measurements of cryosections of individual muscle sections, and its quantification by auto fluorescence is a laborious and time-consuming process. Study design: Both sham and thermal injury techniques were followed. The evaluation of EBD was done to assess the effectiveness of two compounds in the...Read More
The 7H-indolo[30 ,20 :4,5]furo[2,3-b]quinoxaline derivatives are synthesized directly from methyl 2-(2- chloro-1H-indol-3-yl)-2-oxoacetate or its N-alkyl derivatives under neutral or mildly acidic conditions. This new one-pot methodology was found to be general and greener as it avoids the use of environmentally harmful POCl3 and strong alkali required for the pr...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Cholecalciferol, also known as Vitamin D3, is widely prescribed for the treatment osteomalacia and osteoporosis . It also plays a key role in calcium and phosphorus homeostasis and skeletal mineralization . IUPAC name of Cholecalciferol is (3β, 5Z, 7E)- 9,10-secocholesta-5,7,10(19)-trien-3-ol, whose molecular weight is 384.64 g/mol and its molecular formul...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.